Placebo | MPDN | P | |
---|---|---|---|
N patients | 22 (14 m/8 f) | 23 (16 m/4 f) | ns |
Age (years) | 61 (48 to 66) | 66 (49 to 70) | ns |
Comorbidity conditions | |||
COPD | 2 | 4 | ns |
Cardiovascular disease | 2 | 4 | ns |
Diabetes melllitus | 4 | 2 | ns |
Symptoms | |||
Fever >38.5°C | 18 | 20 | |
Cough | 14 | 18 | ns |
Breathlessness | 17 | 16 | ns |
Expectoration | 10 | 10 | ns |
Chest pain | 10 | 11 | ns |
Chills | 13 | 14 | ns |
Altered mental status | 0 | 0 | ns |
Duration of symptoms (days) | 5 (3 to 8) | 5 (3 to 7) | ns |
Clinical signs | |||
Temperature* | 38.6 (38 to 39) | 38.5 (37.6 to 39.5) | ns |
Heart rate* | 102 (96 to 125) | 109 (100 to 120) | ns |
Respiratory rate* | 32 (30 to 40) | 35 (30 to 38) | ns |
Blood tests | |||
White cell × 109* | 10.2 (7.4 to 13.5) | 13.5 (11.4 to 15.6) | 0.01 |
Urea (mmol/dl) * | 7 (5 to 12) | 9 (7 to 12) | ns |
pO2/FiO2* | 257 (209 to 276) | 200 (233 to 236) | ns |
Radiological findings | |||
Bilobar | 11 (50%) | 15 (65%) | ns |
Multilobar | 11 (50%) | 8 (35%) | ns |
Previous antibiotic treatment | 5 (23%) | 4 (17%) | ns |
SAPS* | 7 (6 to 12) | 8 (5 to12) | ns |
Fine Score | |||
I | 0 (0%) | 0 (0%) | ns |
II | 3 (14%) | 1 (4%) | ns |
III | 7 (32%) | 6 (26%) | ns |
IV | 11 (50%) | 14 (61%) | ns |
V | 1 (4%) | 1 (4%) | ns |